Moleculin Biotech (NASDAQ:MBRX) Given New $3.00 Price Target at HC Wainwright

Moleculin Biotech (NASDAQ:MBRX) had its target price dropped by research analysts at HC Wainwright from $22.00 to $3.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 335.60% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. Wall Street Zen raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.00.

Moleculin Biotech Price Performance

MBRX opened at $0.69 on Friday. The company has a market capitalization of $13.42 million, a price-to-earnings ratio of -0.10 and a beta of 1.83. The firm’s fifty day moving average price is $1.66 and its two-hundred day moving average price is $2.25. Moleculin Biotech has a 1 year low of $0.16 and a 1 year high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last announced its earnings results on Thursday, August 13th. The company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.55) by $0.15. As a group, equities analysts anticipate that Moleculin Biotech will post -3.01 EPS for the current year.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is owned by institutional investors and hedge funds.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.